Self-Service Blood Pressure Kiosks; the FLAVOUR Trial & Intermediate Coronary Stenosis; CPAP & Cardiovascular Outcomes
Eagle's Eye View: Your Weekly CV Update From ACC.org
Release Date: 08/27/2025
ORBITA-2 & PCI In Older Adults; Smartwatches and AFib Detection; Improved Management and Treatment of HF and HFrFF
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at the ORBITA-2 trial and how percutaneous coronary intervention (PCI) may lead to greater symptom relief in older adults. He then explores the EQUAL trial that investigated how Apple smartwatch monitoring improves atrial fibrillation (AFib) detection. Finally, Dr. Eagle examines revelations from the EMPEROR-Preserved trial regarding interaction between SGLT2 inhibitors and baseline magnesium levels...
info_outline
Exercise Testing & Systolic Blood Pressure; the Navitor TAVR valve; the ABILITY Diabetes Global Trial & Stent Comparisons for People with Diabetes
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at exercise systolic blood pressure (SBP) during stress testing related to cardiovascular (CV) events. He then explores the novel Navitor transcatheter heart valve (THV) and its safety and effectiveness in younger patients requiring transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle examines the value of 18F-FAPI PET/CT imaging and its role in assessing risk in patients...
info_outline
The State of CV Health in the US; Semaglutide and Reduced Hospital Admissions; D-Dimer and Its Use in Ruling Out DVT
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle comments on the recently published JACC Cardiovascular (CV) Statistics report which evaluates the management of CV risk factors in the United States. He then explores the use of semaglutide and its association with reduced hospital admissions and length of stay. Finally, Dr. Eagle examines the multicenter, multinational ADJUST-DVT study on the age-adjusted use of D-dimer cut-offs for patients with...
info_outline
Reducing Fat & Reducing Mortality & Stroke; Tirzepatide s. Dulaglutide; Finerenone and Hypotension; Low Operator Volume and Worse Outcomes
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle evaluates the impacts that reducing saturated fat have on mortality, nonfatal myocardial infarction (NFMI), and stroke in high-risk individuals. He then explores the SURPASS-CVOT study which considers if tirzepatide is superior to dulaglutide in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). Next, he summarizes the FINEARTS-HF study and its investigation of finerenone and hypotension and CV outcomes according to...
info_outline
Eagle’s Eye View: Top 2025 ACC Content
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this episode, Dr. Eagle looks back at 2025 and explores some of the significant developments that show how the College is responding to changes in the way we evaluate, manage, and follow patients with various types of cardiovascular disorders. His survey of topics that received the most attention include the new guidelines on hypertension, acute coronary syndromes, the management of adults with congenital heart disease, cardiogenic shock, pericarditis, sports cardiology, weight management, amyloid heart disease and...
info_outline
Weight Reversal Post Tirzepatide Withdrawal
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at the DANISH trial extended follow-up, evaluating which patients benefit most from primary prevention implantable cardioverter defibrillator (ICD) implantation. He then explores the SURMOUNT-4 study on weight reversal post tirzepatide withdrawal. Finally, Dr. Eagle examines two JACC articles that cover disease monitoring: one tracking the progression of transthyretin amyloid cardiomyopathy (ATTR-CM) and...
info_outline
The PREVENT Equations & Cardiovascular Risk, the CREST-2 Trials on Carotid Disease , Physician Burnout, Food Labeling & CV Health
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at the use of PREVENT equations to assess cardiovascular (CV) disease risk and the CREST-2 randomized trials that examined stenting versus endarterectomy for asymptomatic carotid disease. He then explores physician burnout and the use of coaching to help treat it. Finally, Dr. Eagle explores how clearer, “front of package” food labeling in grocery stores can provide consumers with practical, science-based guidance to...
info_outline
Improving The Culture and Climate Surrounding Cardiology
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at the potential for electrophysiology (EP) ablation in ambulatory care. He then explores several new studies that reveal the rising rates of heart failure and hypertension. Finally, Dr. Eagle discusses a very important new survey from ACC on the need to improve the professional climate and culture for US cardiologists and trainees.
info_outline
Gastrointestinal Bleeding After LAAO, Lifestyle Modification & Metabolic Syndrome, Beta-Blockers & the Treatment of Preserved LVEF
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at gastrointestinal bleeding (GIB) after left atrial appendage occlusion (LAAO). He then explores lifestyle modifications to treat metabolic syndrome. Finally, Dr. Eagle examines a recent study which found that beta-blockers failed to reduce death, myocardial infarction (MI) or heart failure (HF) in patients with preserved left ventricular ejection fraction (LVEF).
info_outline
Eagle’s Eye View: Highlights from the 2025 AHA Scientific Sessions
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle highlights several important studies presented at the recent American Heart Association Scientific Sessions. The OCEAN Trial on antithrombotic and stroke prevention in patients with atrial fibrillation (AFib). He then explores VESALIUS-CV, a study on evolocumab versus placebo in patients with atherosclerosis or diabetes and without previous myocardial infarction (MI) or stroke. Finally, Dr. Eagle discusses the POLY-HF study on the use of a daily polypill that boosts heart function, improves quality of life, and cuts hospitalizations in underserved...
info_outlineIn this week’s View, Dr. Eagle evaluates the potential value of self-service blood pressure (BP) kiosks and their potential to improve hypertensive health nationwide. He then discusses the FLAVOUR trial and its comparable outcomes with fractional flow reserve (FFR) and intravascular ultrasound (IVUS)-guided treatment for intermediate coronary stenosis. Finally, Dr. Eagle explores how continuous positive airway pressure {CPAP} may improve cardiovascular outcomes in patients with high-risk obstructive sleep apnea (OSA).